Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation

Journal of Korean Medical Science

Volumn 28, Issue 1, 2013, Pages 80-86

  Lee, Ho Sup ^a   Kim, Yang Soo ^a   Kim, Kihyun ^b   Kim, Jin Seok ^c   Kim, Hyo Jung ^d   Min, Chang Ki ^e   Suh, Cheolwon ^f   Eom, Hyeon Seok ^g   Yoon, Sung Soo ^h   Lee, Jae Hoon ⁱ   Kim, Min Kyong ^j   Kim, Sung Hyun ^k   Bae, Sung Hwa ^l   Mun, Yeung Chul ^m   Jo, Deog Yeon ⁿ   Chung, Joo Seop ^o  

^a Kosin University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Hallym University   (South Korea)

^e The Catholic University of Korea   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

^g National Cancer Center   (South Korea)

^h Seoul National University Hospital   (South Korea)

ⁱ Gachon University   (South Korea)

^j Yeungnam University College of Medicine   (South Korea)

^k Dong A University College of Medicine   (South Korea)

^l Catholic University of Daegu   (South Korea)

^m Ewha Womans University School of Medicine   (South Korea)

ⁿ Chungnam National University College of Medicine   (South Korea)

^o Pusan National University School of Medicine   (South Korea)

more..

Author keywords

Bortezomib; Early Response; Multiple Myeloma; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; PYRAZINE DERIVATIVE;

AGED; ARTICLE; DISEASE FREE SURVIVAL; DRUG COMBINATION; EARLY RESPONSE; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTIPLE MYELOMA; PREDICTIVE VALUE; REGISTER; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; SURVIVAL; TREATMENT OUTCOME;

BORTEZOMIB; EARLY RESPONSE; MULTIPLE MYELOMA; SURVIVAL;

AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PREDICTIVE VALUE OF TESTS; PYRAZINES; REGISTRIES; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84874778308     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2013.28.1.80     Document Type: Article

References (25)

1. Facon T, Mary JY, Pegourie B, Attal M, Renaud M, Sadoun A, Voillat L, Dorvaux V, Hulin C, Lepeu G, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006; 107: 1292-8.
2. Hernandez JM, Garcia-Sanz R, Golvano E, Blade J, Fernandez-Calvo J, Trujillo J, Soler JA, Gardella S, Carbonell F, Mateo G, et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 2004; 127: 159-64.
3. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990; 33: 86-9.
4. Segeren CM, Sonneveld P, vanderHolt B, Baars JW, Biesma DH, Cornellissen JJ, Croockewit AJ, Dekker AW, Fibbe WE, Löwenberg B, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 1999; 105: 127-30.
5. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ. High-dose chemotherapy with hematopoietic stemcell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-83.
6. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, Wisloff F, Brinch L, Carlson K, Carlsson M, et al. Impact on survival of highdose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 2000; 95: 7-11.
7. Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. New drugs for myeloma. Oncologist 2007; 12: 664-89.
8. Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson KC. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther 2008; 8: 1053-72.
9. Gertz MA, Kumar S, Lacy MQ, Dispenzieri A, Dingli D, Hayman SR, Buadi FK, Hogan WJ. Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood 2010; 115: 2348-53.
10. Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM,Yoon SS, Lee JH. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Biol Blood Marrow Transplant 2009; 15: 463-70.
11. Kyle RA, Leong T, Li S, Oken MM, Kay NE, VanNess B, Greipp PR. Complete response in multiple myeloma: clinical trial E9486, an Eastern CooperativeOncology Group study not involving stem cell transplantation. Cancer 2006; 106: 1958-66.
12. Offidani M, Corvatta L, Piersantelli MN, Visani G, Alesiani F, Brunori M, Galieni P, Catarini M, Burattini M, Centurioni R, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patientsolder than 65 years with newly diagnosed multiple myeloma. Blood 2006; 108: 2159-64.
13. Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, Montanaro M, Ria R, Capaldi A, Zambello R, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008; 112: 3107-14.
14. Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, Dib M, Guillerm G, Salles B, Eschard JP, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009; 27: 3664-70.
15. Ross DM, To LB, Horvath N. Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma. Intern Med J 2004; 34: 576-8.
16. Palumbo A. Early response predicts myeloma outcome. Blood 2010; 115: 2332-3.
17. Schaar CG, Kluin-Nelemans JC, le Cessie S, Franck PF, te Marvelde MC, Wijermans PW. Early response to therapy and survival in multiple myeloma. Br J Haematol 2004; 125: 162-6.
18. Ludwig H, Hajek R, Tothova E, Drach J, Adam Z, Labar B, Egyed M, Spicka I, Gisslinger H, Greil R, et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009; 113: 3435-42.
19. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Renaud M, Harousseau JL, Guillerm G, Chaleteix C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced- intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370: 1209-18.
20. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-17.
21. Shah J, Blade J, Sonneveld P, Harousseau JL, Lantz K, Londhe A, Lowery C, Orlowski RZ. Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression. Cancer 2011; 117: 3758-62.
22. Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009; 23: 1716-30.
23. Harousseau JL, Palumbo A, Richardson PG, Schlag R, Dimopoulos MA, Shpilberg O, Kropff M, Kentos A, Cavo M, Golenkov A, et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood 2010; 116: 3743-50.
24. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, Crippa C, Ciccone G, Omedè P, Ambrosini MT, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007; 25: 4459-65.
25. Gay F, Vincent Rajkumar S, Falco P, Kumar S, Dispenzieri A, Petrucci MT, Gertz MA, Boccadoro M, Keith Stewart A, Palumbo A. Lenalidomide plus dexamethasone vs lenalidomide plus melphalan and prednisone:a retrospective study in newly diagnosed elderly myeloma. Eur J Haematol 2010; 85: 200-8.